Cervical cancer screening and prevention

K. J. Mahlaba, V. V. Nkwinika, R. L. Lebelo, J. C. Meyer*, R. J. Burnett

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite cervical cancer being a vaccine-preventable disease, and being treatable if diagnosed in the early stages, it is the third most common cancer among women in terms of both global incidence and cause of cancer deaths, affecting mostly low- and middle-income countries. Persistent infection of the cervix with high-risk types of human papillomavirus (HPV) is the necessary (but not sufficient) cause of cervical cancer. These infections are sexually transmitted and can be prevented or reduced through vaccination before sexual debut, and managed if detected early through cervical cancer screening programmes. This review offers insight into the challenges faced in South Africa regarding the prevention of cervical cancer, and the role of pharmacists in addressing these challenges.

Original languageEnglish
Pages (from-to)16-21
Number of pages6
JournalSA Pharmaceutical Journal
Volume87
Issue number4
Publication statusPublished - 1 Jan 2020

Keywords

  • Cervical cancer
  • Human papillomavirus (HPV)
  • Human papillomavirus vaccine

Fingerprint

Dive into the research topics of 'Cervical cancer screening and prevention'. Together they form a unique fingerprint.

Cite this